Elgemtumab

• CAT Number: I041524
• CAS Number: 1512559-37-3
• Purity: ≥95%

Elgemtumab(LJM716) is a fully human IgG monoclonal antibody. Elgemtumab can specifically bind to HER3, block ligand-dependent and independent HER3 signal transduction and cell proliferation, and has good anti-tumor potential[1].
Elgemtumab(LJM716)(i.v., 20 mg/kg,once) can reduce pHER3 by 52% and pAKT by 84% in SCID mice with BT474 breast cancer xenografts; while in BxPC-3 pancreatic xenografts In SCID mice, it resulted in a maximum inhibition of pHER3 of 86% and a maximum inhibition of pAKT of 74%[1].
Elgemtumab (LJM716) (20 mg/kg, every other day, 35 days) slows tumor growth in NSG mice with BT474 breast cancer xenografts[1].

Reference

[1]. Andrew P Garner, et al. An antibody that locks HER3 in the inactive conformation inhibits tumor growth driven by HER2 or neuregulin. Cancer Res. 2013 Oct 1;73(19):6024-35.
 [Content Brief]